Catalytic iron and acute kidney injury

American Journal of Physiology - Renal Physiology

Volumn 311, Issue 5, 2016, Pages F871-F876

  Leaf, David E ^a   Swinkels, Dorine W ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

AKI; Ferritin; HO 1; Labile iron; Non transferrin bound iron

Indexed keywords

CATALYTIC IRON; CD163 ANTIGEN; CONTRAST MEDIUM; FERRITIN; HAPTOGLOBIN; HEME OXYGENASE 1; IRON; IRON CHELATING AGENT; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ARTICLE; BLOOD SAMPLING; CATALYSIS; CONTRAST INDUCED NEPHROPATHY; CRITICAL ILLNESS; DISEASE ASSOCIATION; HEART SURGERY; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ACUTE KIDNEY INJURY; ANIMAL; DISEASE MODEL;

ACUTE KIDNEY INJURY; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IRON;

EID: 84994592289     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00388.2016     Document Type: Article

References (57)

1. Baek JH, D’Agnillo F, Vallelian F, Pereira CP, Williams MC, Jia Y, Schaer DJ, Buehler PW. Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. J Clin Invest 122: 1444-1458, 2012.
2. Baliga R, Ueda N, Shah SV. Increase in bleomycin-detectable iron in ischaemia/reperfusion injury to rat kidneys. Biochem J 291: 901-905, 1993.
3. Baliga R, Zhang Z, Baliga M, Shah SV. Evidence for cytochrome P-450 as a source of catalytic iron in myoglobinuric acute renal failure. Kidney Int 49: 362-369, 1996.
4. Baliga R, Zhang Z, Baliga M, Ueda N, Shah SV. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int 53: 394-401, 1998.
5. Balla G, Jacob HS, Balla J, Rosenberg M, Nath K, Apple F, Eaton JW, Vercellotti GM. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem 267: 18148-18153, 1992.
6. Bolisetty S, Zarjou A, Hull TD, Traylor AM, Perianayagam A, Joseph R, Kamal AI, Arosio P, Soares MP, Jeney V, Balla J, George JF, Agarwal A. Macrophage and epithelial cell H-ferritin expression regulates renal inflammation. Kidney Int 88: 95-108, 2015.
7. Brissot P, Ropert M, Le Lan C, Loreal O. Non-transferrin bound iron:a key role in iron overload and iron toxicity. Biochim Biophys Acta 1820:403-410, 2012.
8. Burkitt MJ, Milne L, Raafat A. A simple, highly sensitive and improved method for the measurement of bleomycin-detectable iron: the "catalytic iron index" and its value in the assessment of iron status in haemochromatosis. Clin Sci (Lond) 100: 239-247, 2001.
9. Cabantchik ZI. Labile iron in cells and body fluids: physiology, pathology, and pharmacology. Front Pharmacol 5:45, 2014.
10. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16: 3365-3370, 2005.
11. Davis CL, Kausz AT, Zager RA, Kharasch ED, Cochran RP. Acute renal failure after cardiopulmonary bypass in related to decreased serum ferritin levels. J Am Soc Nephrol 10: 2396-2402, 1999.
12. de Swart L, Hendriks JC, van der Vorm LN, Cabantchik ZI, Evans PJ, Hod EA, Brittenham GM, Furman Y, Wojczyk B, Janssen MC, Porter JB, Mattijssen VE, Biemond BJ, MacKenzie MA, Origa R, Galanello R, Hider RC, Swinkels DW. Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders. Haematologica 101:38-45, 2016.
13. de Vries B, Walter SJ, von Bonsdorff L, Wolfs TG, van Heurn LW, Parkkinen J, Buurman WA. Reduction of circulating redox-active iron by apotransferrin protects against renal ischemia-reperfusion injury. Transplantation 77: 669-675, 2004.
14. Doherty DH, Doyle MP, Curry SR, Vali RJ, Fattor TJ, Olson JS, Lemon DD. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotechnol 16: 672-676, 1998.
15. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102: 2670-2677, 2003.
16. Evans PJ, Halliwell B. Measurement of iron and copper in biological systems: bleomycin and copper-phenanthroline assays. Methods Enzymol 233: 82-92, 1994.
17. Evans RW, Rafique R, Zarea A, Rapisarda C, Cammack R, Evans PJ, Porter JB, Hider RC. Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. J Biol Inorg Chem 13: 57-74, 2008.
18. Fraga CM, Tomasi CD, Biff D, Topanotti MF, Felisberto F, Vuolo F, Petronilho F, Dal-Pizzol F, Ritter C. The effects of N-acetylcysteine and deferoxamine on plasma cytokine and oxidative damage parameters in critically ill patients with prolonged hypotension: a randomized controlled trial. J Clin Pharmacol 52: 1365-1372, 2012.
19. Garg AX, Whitlock RP. Effect of methylprednisolone on acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass. In: Proceedings of the High-Impact Clinical Trials, American Society of Nephrology Kidney Week, San Diego, CA, November 7, 2015. Washington, DC: American Society of Nephrology, 2015.
20. Goldstein JI, Goldstein KA, Wardwell K, Fahrner SL, Goonan KE, Cheney MD, Yeager MP, Guyre PM. Increase in plasma and surface CD163 levels in patients undergoing coronary artery bypass graft surgery. Atherosclerosis 170: 325-332, 2003.
21. Graw JA, Rosales IA, Liu YL, Sabbisetti VS, Riley FE, Rechester O, Bloch KD, Warren HS, Bonventre JV, Zapol WM. Haptoglobin therapy prevents kidney injury in stored blood resuscitation of murine hemorrhagic shock (Abstract). Blood 124:761, 2014.
22. Halliwell B, Aruoma OI, Mufti G, Bomford A. Bleomycin-detectable iron in serum from leukaemic patients before and after chemotherapy. Therapeutic implications for treatment with oxidant-generating drugs. FEBS Lett 241: 202-204, 1988.
23. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 186: 1-85, 1990.
24. Hanss BG, Valencia SH, Shah SV, Vari RC. The iron chelator deferoxamine prevents contrast media induced acute renal failure in the rabbit (Abstract). J Am Soc Nephrol 1:612, 1990.
25. Hider RC, Silva AM, Podinovskaia M, Ma Y. Monitoring the efficiency of iron chelation therapy: the potential of nontransferrin-bound iron. Ann N Y Acad Sci 1202: 94-99, 2010.
26. Huang WF, Chou HC, Tsai YW, Hsiao FY. Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events. Pharmacoepidemiol Drug Saf 23: 1176-1182, 2014.
27. Itkonen O, Vaahtera L, Parkkinen J. Comparison of bleomycin-detectable iron and labile plasma iron assays. Clin Chem 59: 1271-1273, 2013.
28. Jacob AK, Hotchkiss RS, DeMeester SL, Hiramatsu M, Karl IE, Swanson PE, Cobb JP, Buchman TG. Endothelial cell apoptosis is accelerated by inorganic iron and heat via an oxygen radical dependent mechanism. Surgery 122: 243-254, 1997.
29. Jacob KA, Leaf DE, Dieleman JM, van Dijk D, Nierich AP, Rosseel PM, van der Maaten JM, Hofland J, Diephuis JC, de Lange F, Boer C, Kluin J, Waikar SS; Dexamethasone for Cardiac Surgery Study Group. Intraoperative high-dose dexamethasone and severe AKI after cardiac surgery. J Am Soc Nephrol 26: 2947-2951, 2015.
30. Jeney V, Balla J, Yachie A, Varga Z, Vercellotti GM, Eaton JW, Balla G. Pro-oxidant and cytotoxic effects of circulating heme. Blood 100:879-887, 2002.
31. Leaf DE, Body SC, Muehlschlegel JD, McMahon GM, Pichtner P, Collard CD, Shernan SK, Fox AA, Waikar SS. Length polymorphisms in heme oxygenase-1 and AKI after cardiac surgery. J Am Soc Nephrol. [Epub before print].
32. Leaf DE, Rajapurkar M, Lele SS, Mukhopadhyay B, Rawn JD, Frendl G, Waikar SS. Increased plasma catalytic iron in patients may mediate acute kidney injury and death following cardiac surgery. Kidney Int 87: 1046-1054, 2015.
33. Leaf DE, Rajapurkar M, Lele SS, Mukhopadhyay B, Waikar SS. Plasma catalytic iron, AKI, and death among critically ill patients. Clin J Am Soc Nephrol 9: 1849-1856, 2014.
34. Lele SS, Mukhopadhyay BN, Mardikar MM, Patel TA, Vasavada AK, Banker DN, Kapasi KD, Chauhan VC, Chawla KC, Raju SR, Hiremath SS, Chinchole SS, Rajapurkar MM. Impact of catalytic iron on mortality in patients with acute coronary syndrome exposed to iodinated radiocontrast-the ISCOM study. Am Heart J 165: 744-751, 2013.
35. Lever JM, Boddu R, George JF, Agarwal A. Heme oxygenase-1 in kidney health and disease. Antioxid Redox Signal 25: 165-183, 2016.
36. Martines AM, Masereeuw R, Tjalsma H, Hoenderop JG, Wetzels JF, Swinkels DW. Iron metabolism in the pathogenesis of iron-induced kidney injury. Nat Rev Nephrol 9: 385-398, 2013.
37. Menasche P, Antebi H, Alcindor LG, Teiger E, Perez G, Giudicelli Y, Nordmann R, Piwnica A. Iron chelation by deferoxamine inhibits lipid peroxidation during cardiopulmonary bypass in humans. Circulation 82, Suppl: IV390-IV396, 1990.
38. Menasche P, Pasquier C, Bellucci S, Lorente P, Jaillon P, Piwnica A. Deferoxamine reduces neutrophil-mediated free radical production during cardiopulmonary bypass in man. J Thorac Cardiovasc Surg 96: 582-589, 1988.
39. Mishra J, Mori K, Ma Q, Kelly C, Yang J, Mitsnefes M, Barasch J, Devarajan P. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 15: 3073-3082, 2004.
40. Nath KA. Heme oxygenase-1 and acute kidney injury. Curr Opin Nephrol Hypertens 23: 17-24, 2014.
41. Nath KA, Balla G, Vercellotti GM, Balla J, Jacob HS, Levitt MD, Rosenberg ME. Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. J Clin Invest 90: 267-270, 1992.
42. Nilsson A, Vesterlund L, Oldenborg PA. Macrophage expression of LRP1, a receptor for apoptotic cells and unopsonized erythrocytes, can be regulated by glucocorticoids. Biochem Biophys Res Commun 417: 1304-1309, 2012.
43. Paller MS. Hemoglobin- and myoglobin-induced acute renal failure in rats: role of iron in nephrotoxicity. Am J Physiol Renal Fluid Electrolyte Physiol 255:F539-F544, 1988.
44. Paller MS, Hedlund BE. Role of iron in postischemic renal injury in the rat. Kidney Int 34: 474-480, 1988.
45. Paraskevaidis IA, Iliodromitis EK, Vlahakos D, Tsiapras DP, Nikolaidis A, Marathias A, Michalis A, Kremastinos DT. Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance. Eur Heart J 26: 263-270, 2005.
46. Ponka P. Cell biology of heme. Am J Med Sci 318: 241-256, 1999.
47. Schaer DJ, Buehler PW, Alayash AI, Belcher JD, Vercellotti GM. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 121:1276-1284, 2013.
48. Schaer DJ, Schaer CA, Buehler PW, Boykins RA, Schoedon G, Alayash AI, Schaffner A. Cd163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. Blood 107: 373-380, 2006.
49. Seixas E, Gozzelino R, Chora A, Ferreira A, Silva G, Larsen R, Rebelo S, Penido C, Smith NR, Coutinho A, Soares MP. Heme oxygenase-1 affords protection against noncerebral forms of severe malaria. Proc Natl Acad Sci U S A 106: 15837-15842, 2009.
50. Shah SV, Rajapurkar MM, Baliga R. The role of catalytic iron in acute kidney injury. Clin J Am Soc Nephrol 6: 2329-2331, 2011.
51. Silva AM, Hider RC. Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron. Implications for non-transferrin-bound iron speciation. Biochim Biophys Acta 1794:1449-1458, 2009.
52. Tuttle KR, Worrall NK, Dahlstrom LR, Nandagopal R, Kausz AT, Davis CL. Predictors of ARF after cardiac surgical procedures. Am J Kidney Dis 41: 76-83, 2003.
53. Waikar SS, Curhan GC, Wald R, McCarthy EP, Chertow GM. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 17: 1143-1150, 2006.
54. Waikar SS, Liu KD, Chertow GM. The incidence and prognostic significance of acute kidney injury. Curr Opin Nephrol Hypertens 16:227-236, 2007.
55. Walker PD, Shah SV. Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats. J Clin Invest 81: 334-341, 1988.
56. Zager RA. Combined mannitol and deferoxamine therapy for myohemoglobinuric renal injury and oxidant tubular stress. Mechanistic and therapeutic implications. J Clin Invest 90: 711-719, 1992.
57. Zarjou A, Bolisetty S, Joseph R, Traylor A, Apostolov EO, Arosio P, Balla J, Verlander J, Darshan D, Kuhn LC, Agarwal A. Proximal tubule H-ferritin mediates iron trafficking in acute kidney injury. J Clin Invest 123: 4423-4434, 2013.